retatrutide glp-1 gip glucagon triple agonist Synedica New obesity drugs are coming,

While this particular study has yet to be published in a peer-reviewed journal, another study published in February in the Journal of Clinical Endocrinology & Metabolism connected the medications with a higher risk of getting osteoporosis-related fractures for older adults with type 2 diabetes

Starting a GLP-1 for RA is a clinical decision that should account for your disease activity, your other conditions, and your goals

This is the highest and most prominent safety-related warning that the U.S

Glucagon-like peptide 2 counteracts the mucosal damage and the neuropathy induced by chronic treatment with cisplatin in the mouse gastric fundus